首次引入市场独占期制度，最长达7年

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" will take effect on May 15, marking the first comprehensive revision in 23 years, aimed at encouraging innovation and improving drug accessibility [1]. Group 1: Encouragement of Innovation and Fast-Track Approval - The revision emphasizes encouraging innovation, supporting the research and creation of new drugs based on clinical value, and improving the quality and efficacy of generic drugs [2]. - The regulations establish a fast-track approval process for new drugs, including breakthrough therapies and conditional approvals, to expedite the availability of effective medications to patients [2]. - Research data obtained overseas can now be used for drug registration in China, facilitating the early introduction of global innovative drugs [2]. Group 2: Intellectual Property Protection and Market Exclusivity - The revised regulations introduce a market exclusivity period for drug trial data, enhancing intellectual property protection for pharmaceutical companies [3]. - During the data protection period, innovative drug companies can achieve reasonable returns, which supports ongoing research and development [3]. - The market exclusivity period will be extended to rare disease medications and pediatric drugs, with a maximum of 7 years for rare diseases and 2 years for pediatric drugs [4]. Group 3: Online Drug Sales Regulation - The new regulations clarify the responsibilities of online drug sales platforms, emphasizing that companies are responsible for their products while platforms must ensure compliance and safety [5]. - Platforms are required to establish dedicated teams and systems to manage the qualifications of vendors and monitor drug transactions [5]. - The regulations also allow for segmented production and clarify that commercially scaled batches of drugs can be marketed, enhancing the regulatory framework for the pharmaceutical industry [5].